吡格列酮對重度至極重度突發性感音神經性聽力損失標準類固醇治療無增益作用

// Pioglitazone does not improve standard steroid therapy for severe to profound sudden sensorineural hearing loss

這項隨機對照試驗評估了匹格列酮（糖尿病用藥）作為突發性聽力損失或聲音創傷患者的皮質類固醇輔助治療｜參與者於症狀出現96小時內接受標準皮質類固醇加匹格列酮或安慰劑｜結果顯示聽力皆有顯著改善，但匹格列酮未帶來額外益處｜研究結論指出匹格列酮無助於恢復，且調整皮質類固醇劑量或治療時間亦無顯著效果。

// This randomized controlled trial tested pioglitazone as an add-on to corticosteroids in patients with sudden hearing loss or acoustic trauma. Participants received standard corticosteroid treatment plus either pioglitazone or placebo within 96 hours of symptom onset. While hearing improved significantly across all groups, pioglitazone provided no extra benefit over placebo. The study concludes pioglitazone does not enhance recovery, and varying corticosteroid dose or duration showed no additional effect.

Published 2026年6月24日